PMID- 34585897
OWN - NLM
STAT- MEDLINE
DCOM- 20211001
LR  - 20211001
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 69
IP  - 9
DP  - 2021 Sep
TI  - Current Role of Dapagliflozin in Clinical Practice.
PG  - 11-12
AB  - Dapagliflozin is the first in a novel class of glucose-lowering agents known as 
      sodium-glucose co-transporter-2 (SGLT2) inhibitors which was approved by USFDA in 
      management of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise 
      to improve glycemic control in adults initially, followed by to reduce the risk 
      of hospitalization for heart failure (HHF) in adults with T2DM and established 
      cardiovascular disease or multiple cardiovascular risk factors. Most recently, it 
      is approved to reduce the risk of cardiovascular death and in adults with heart 
      failure (HF) with reduced ejection fraction (NYHA class II-IV). Dapagliflozin has 
      been studied in a wide range of patients with diabetes and plethora of evidence 
      has confirmed its efficacy as a monotherapy as well as an add-on to the oral 
      therapies and insulin, when compared to placebo. Additional advantages include 
      weight reduction which has been consistently demonstrated in Phase III studies 
      and good tolerability. Also there is a demonstrable reduction in systolic blood 
      pressure in patients treated with SGLT2 inhibitors. DECLARE TIMI 58 study clearly 
      demonstrated that Dapagliflozin was non inferior in reducing major adverse 
      cardiovascular events (MACE) in patients with T2DM and high CV risk compared with 
      placebo. 27% risk reduction in heart failure hospitalisation was noted along 
      without increased risk of amputation. DAPA HF evaluated the efficacy and safety 
      of the dapagliflozin in patients with HF and reduced ejection fraction, 
      irrespective of the presence or absence of diabetes. Patients with symptomatic HF 
      due to reduced ejection fraction treated with dapagliflozin had positive outcomes 
      with reduction in cardiovascular deaths and HF events. The DAPA-CKD trial which 
      was conducted to assess the efficacy and safety of dapagliflozin in patients with 
      chronic kidney disease (CKD), with or without type 2 diabetes found that it 
      significantly lowered the risk of a sustained decline in the estimated GFR of at 
      least 50%, end-stage kidney disease, or death from renal or cardiovascular causes 
      in patients with CKD, regardless of the presence or absence of diabetes. Ongoing 
      trials like DELIVER, DAPA ACT HF-TIMI 68, DICTATE-AHF, HF readmission study, DAPA 
      MI Study, Effectiveness of Dapagliflozin for Weight Loss, will throw more light 
      on the precise effects of dapagliflozin in several clinical scenarios. To 
      conclude - Dapagliflozin was well studied not only in T2DM but also in HF and CKD 
      patients with positive results and good safety profile.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Zargar, Abdul Hamid
AU  - Zargar AH
AD  - Medical Director, Centre for Diabetes and Endocrine Care, Srinagar, Jammu 
      Kashmir.
FAU - Trailokya, Abhijit Anil
AU  - Trailokya AA
AD  - Pharmaceutical Geriatric Medicine, DGM Medical Affairs, Medical Affairs Team, 
      Alkem Labs., Mumbai, Maharashtra.
FAU - Ghag, Suraj
AU  - Ghag S
AD  - Senior Medical Advisor, Medical Affairs Team, Alkem Labs., Mumbai, Maharashtra.
FAU - Pawar, Roshan
AU  - Pawar R
AD  - Senior Medical Advisor, Medical Affairs Team, Alkem Labs., Mumbai, Maharashtra.
FAU - Aiwale, Amol
AU  - Aiwale A
AD  - Senior Medical Advisor, Medical Affairs Team, Alkem Labs., Mumbai, Maharashtra.
FAU - Zalke, Ashish
AU  - Zalke A
AD  - Medical Advisor, Medical Affairs Team, Alkem Labs., Mumbai, Maharashtra.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glucosides/therapeutic use
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
EDAT- 2021/09/30 06:00
MHDA- 2021/10/02 06:00
CRDT- 2021/09/29 10:57
PHST- 2021/09/29 10:57 [entrez]
PHST- 2021/09/30 06:00 [pubmed]
PHST- 2021/10/02 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2021 Sep;69(9):11-12.